Despite the development of targeted agents for the treatment of HR-positive and HER2-positive breast cancers, cytotoxic chemotherapy remains integral to the treatment of breast cancer, particularly triple-negative breast cancer. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.